Outer Membrane Vesicle-Coated Nanoparticle Vaccine Protects Against Acinetobacter baumannii Pneumonia and Sepsis.

The highly multidrug-resistant (MDR) Gram-negative bacterial pathogen Acinetobacter baumannii is a top global health priority where an effective vaccine could protect susceptible populations and limit resistance acquisition. Outer membrane vesicles (OMVs) shed from Gram-negative bacteria are enriched with virulence factors and membrane lipids but heterogeneous in size and cargo. We report a vaccine platform combining precise and replicable nanoparticle technology with immunogenic A. baumannii OMVs (Ab-OMVs). Gold nanoparticle cores coated with Ab-OMVs (Ab-NPs) induced robust IgG titers in rabbits that enhanced human neutrophil opsonophagocytic killing and passively protected against lethal A. baumannii sepsis in mice. Active Ab-NP immunization in mice protected against sepsis and pneumonia, accompanied by B cell recruitment to draining lymph nodes, activation of dendritic cell markers, improved splenic neutrophil responses, and mitigation of proinflammatory cytokine storm. Nanoparticles are an efficient and efficacious platform for OMV vaccine delivery against A. baumannii and perhaps other high-priority MDR pathogens.

[1]  Pallavi Sharma,et al.  Immunomodulatory effect of mycobacterial outer membrane vesicles coated nanoparticles , 2022, bioRxiv.

[2]  Jiang Ouyang,et al.  Emerging vaccine nanotechnology: From defense against infection to sniping cancer , 2022, Acta Pharmaceutica Sinica B.

[3]  M. Šantak,et al.  Current view on novel vaccine technologies to combat human infectious diseases , 2021, Applied microbiology and biotechnology.

[4]  M. Zhang,et al.  Regulation of the formation and structure of biofilms by quorum sensing signal molecules packaged in outer membrane vesicles. , 2021, The Science of the total environment.

[5]  Ronnie H. Fang,et al.  Physical Disruption of Solid Tumors by Immunostimulatory Microrobots Enhances Antitumor Immunity , 2021, Advanced materials.

[6]  V. Nizet,et al.  Bacterial Membrane-Derived Vesicles Attenuate Vancomycin Activity against Methicillin-Resistant Staphylococcus aureus , 2021, Microorganisms.

[7]  B. Stanton Extracellular Vesicles and Host–Pathogen Interactions: A Review of Inter-Kingdom Signaling by Small Noncoding RNA , 2021, Genes.

[8]  S. McClean,et al.  Mapping Global Prevalence of Acinetobacter baumannii and Recent Vaccine Development to Tackle It , 2021, Vaccines.

[9]  I. Ferlenghi,et al.  Stability of Outer Membrane Vesicles-Based Vaccines, Identifying the Most Appropriate Methods to Detect Changes in Vaccine Potency , 2021, Vaccines.

[10]  Crystal Ma,et al.  Where are we and how far is there to go in the development of an Acinetobacter vaccine? , 2021, Expert review of vaccines.

[11]  C. MacLennan,et al.  Outer membrane vesicle vaccines. , 2020, Seminars in immunology.

[12]  G. Innes,et al.  Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions — New Jersey, February–July 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[13]  Patrick S. Gellings,et al.  Recent Advances in the Pursuit of an Effective Acinetobacter baumannii Vaccine , 2020, Pathogens.

[14]  Jiru Xu,et al.  Risk factors and outcomes of bloodstream infections caused by Acinetobacter baumannii: a case-control study. , 2020, Diagnostic microbiology and infectious disease.

[15]  Hang Zhao,et al.  Multifunctional Gold Nanoparticles: A Novel Nanomaterial for Various Medical Applications and Biological Activities , 2020, Frontiers in Bioengineering and Biotechnology.

[16]  F. Mancini,et al.  Outer membrane vesicles: moving within the intricate labyrinth of assays that can predict risks of reactogenicity in humans , 2020, Human vaccines & immunotherapeutics.

[17]  R. Rappuoli,et al.  Vaccines Against Antimicrobial Resistance , 2020, Frontiers in Immunology.

[18]  P. Hsueh,et al.  Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? , 2020, Journal of Microbiology, Immunology and Infection.

[19]  T. Ren,et al.  Nanoparticle reinforced bacterial outer-membrane vesicles effectively prevent fatal infection of carbapenem-resistant Klebsiella pneumonia. , 2019, Nanomedicine : nanotechnology, biology, and medicine.

[20]  M. McConnell,et al.  A lipopolysaccharide-free outer membrane vesicle vaccine protects against Acinetobacter baumannii infection. , 2019, Vaccine.

[21]  S. Liew,et al.  The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis. , 2019, The Journal of infection.

[22]  R. Bonomo,et al.  Human pleural fluid triggers global changes in the transcriptional landscape of Acinetobacter baumannii as an adaptive response to stress , 2019, Scientific Reports.

[23]  Antibiotic resistance threats in the United States, 2019 , 2019 .

[24]  M. Hamidian,et al.  Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii , 2019, Microbial genomics.

[25]  A. Peleg,et al.  The Mechanisms of Disease Caused by Acinetobacter baumannii , 2019, Front. Microbiol..

[26]  Ronnie H. Fang,et al.  Biomimetic Nanotechnology toward Personalized Vaccines , 2019, Advanced materials.

[27]  Wangxue Chen,et al.  Acute intraperitoneal infection with a hypervirulent Acinetobacter baumannii isolate in mice , 2019, Scientific Reports.

[28]  R. Carlisle,et al.  Novel approaches for the design, delivery and administration of vaccine technologies , 2019, Clinical and experimental immunology.

[29]  J. Rello,et al.  Ventilator-Associated Pneumonia due to Drug-Resistant Acinetobacter baumannii: Risk Factors and Mortality Relation with Resistance Profiles, and Independent Predictors of In-Hospital Mortality , 2019, Medicina.

[30]  U. Baxa,et al.  Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses , 2018, Nature Immunology.

[31]  Maxim Shevtsov,et al.  Nanoparticle Vaccines Against Infectious Diseases , 2018, Front. Immunol..

[32]  B. Velimirov,et al.  Unexpected aspects in the dynamics of horizontal gene transfer of prokaryotes: the impact of outer membrane vesicles , 2018, Wiener Medizinische Wochenschrift.

[33]  K. Jansen,et al.  The role of vaccines in fighting antimicrobial resistance (AMR) , 2018, Human vaccines & immunotherapeutics.

[34]  Ronnie H. Fang,et al.  Cell Membrane Coating Nanotechnology , 2018, Advanced materials.

[35]  D. Martens,et al.  Bioengineering bacterial outer membrane vesicles as vaccine platform. , 2017, Biotechnology advances.

[36]  A. Jan Outer Membrane Vesicles (OMVs) of Gram-negative Bacteria: A Perspective Update , 2017, Front. Microbiol..

[37]  Ronnie H. Fang,et al.  Cell membrane-derived nanomaterials for biomedical applications. , 2017, Biomaterials.

[38]  Ziwen Zhao,et al.  Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality , 2017, BMC Infectious Diseases.

[39]  K. Peters,et al.  A penicillin-binding protein inhibits selection of colistin-resistant, lipooligosaccharide-deficient Acinetobacter baumannii , 2016, Proceedings of the National Academy of Sciences.

[40]  M. Kuehn,et al.  Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions , 2015, Nature Reviews Microbiology.

[41]  M. Stork,et al.  Outer membrane vesicles as platform vaccine technology , 2015, Biotechnology journal.

[42]  M. Roessle,et al.  Fusion of Legionella pneumophila outer membrane vesicles with eukaryotic membrane systems is a mechanism to deliver pathogen factors to host cell membranes , 2015, Cellular microbiology.

[43]  C. Bumroongkit,et al.  Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia , 2015, Journal of Intensive Care.

[44]  Je Chul Lee,et al.  Acinetobacter baumannii Outer Membrane Vesicles Elicit a Potent Innate Immune Response via Membrane Proteins , 2013, PloS one.

[45]  Ronnie H. Fang,et al.  Surface Functionalization of Gold Nanoparticles with Red Blood Cell Membranes , 2013, Advanced materials.

[46]  A. Gorringe,et al.  Bexsero: a multicomponent vaccine for prevention of meningococcal disease. , 2012, Human vaccines & immunotherapeutics.

[47]  M. Adams,et al.  Active and Passive Immunization Protects against Lethal, Extreme Drug Resistant-Acinetobacter baumannii Infection , 2012, PloS one.

[48]  Je Chul Lee,et al.  Acinetobacter baumannii Secretes Cytotoxic Outer Membrane Protein A via Outer Membrane Vesicles , 2011, PloS one.

[49]  K. Yamaguchi,et al.  A New Method for the Evaluation of Vaccine Safety Based on Comprehensive Gene Expression Analysis , 2010, Journal of biomedicine & biotechnology.

[50]  Priyabrata Mukherjee,et al.  Gold nanoparticles: opportunities and challenges in nanomedicine , 2010, Expert opinion on drug delivery.

[51]  Cui Tang,et al.  Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. , 2010, Biomaterials.

[52]  Catherine J. Murphy,et al.  Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? , 2010, Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology.

[53]  J. Cavaillon,et al.  Resilience to bacterial infection: difference between species could be due to proteins in serum. , 2010, The Journal of infectious diseases.

[54]  Y. Gho,et al.  Proteome analysis of outer membrane vesicles from a clinical Acinetobacter baumannii isolate. , 2009, FEMS microbiology letters.

[55]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[56]  Vasso Apostolopoulos,et al.  Pathogen recognition and development of particulate vaccines: does size matter? , 2006, Methods.

[57]  Jie Li,et al.  Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1 , 2004, The Journal of Immunology.

[58]  J. Garnacho-Montero,et al.  Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  B. Zomer,et al.  Meningitis bacterium is viable without endotoxin , 1998, Nature.

[60]  P. Buchy,et al.  Impact of vaccines on antimicrobial resistance. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[61]  C. Esimone,et al.  An assessment, in mice, of the safety of the childhood immunization vaccines sourced from three south-eastern states of Nigeria , 2016 .

[62]  Ronnie H. Fang,et al.  Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. , 2015, Nano letters.

[63]  Chun-Xia Zhao,et al.  Nanoparticle vaccines. , 2014, Vaccine.

[64]  K. Kanik,et al.  Prospective study of antibacterial susceptibility, risk factors and outcome of 157 episodes of Acinetobacter baumannii bacteremia in 1999 in Slovakia. , 2001, Scandinavian journal of infectious diseases.